Methylene blue as a diagnostic aid in the early detection and screening of oral cancers and precancerous lesion.
Main Article Content
Abstract
Objective: to assess the reliability and sensitivity of in vivo methylene blue staining as a diagnostic tool for screening of oral malignant and premalignant lesions.
Methodology: The study was conducted at oral and maxillofacial surgery department Foundation University College of Dentistry & Hospital, Islamabad, from October 2023 to December 2024. The screening for oral cancers and precancerous lesions was conducted on 77 patients. Clinical data on patients’ gender, age, followed by a systematic oral examination to clinically diagnose suspicious lesions on routine examination. Chair side Methylene blue dye uptake was compared with Biopsy report (Gold standard).
Results: Out of 77 patients, 64 patients showed to be having oral cancer. The result indicated sensitivity of 93.8%, specificity of 53.8%, positive predictive value of 90.9%, negative predictive value of 63.6% and accuracy of 87%.
Conclusion: Methylene blue staining is a reliable diagnostic tool for oral cancer screening, particularly for high-risk individuals. Its utility is especially significant in settings where access to advanced diagnostic tools may be limited, as it provides a cost-effective, non-invasive, and relatively simple method to improve diagnostic accuracy and prioritize individuals for further evaluation or biopsy.
Keywords: Methylene blue, Dysplasia, Oral mucosa, Malignant lesion, Cancer
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
